2025
A Matrigel-Free 3D Chondrocytic Spheroid Model for Rheumatoid Arthritis-Associated Synoviocytes Invasion Studies
Zhao Y, Yang X, Yao F, Ouyang Z, Hu W, Li L, Cheng J, Wang K, Ding J, Zheng L, Qu B, Sun C, Li S, Jiang C, Chen Y, Zhou R, Hu W. A Matrigel-Free 3D Chondrocytic Spheroid Model for Rheumatoid Arthritis-Associated Synoviocytes Invasion Studies. Journal Of Inflammation Research 2025, 18: 4319-4334. PMID: 40162078, PMCID: PMC11952051, DOI: 10.2147/jir.s504701.Peer-Reviewed Original ResearchChondrocyte spheroidsCartilage extracellular matrixArticular cartilageExtracellular matrixSensitive to genesDepth ratioCatabolism-related genesThree-dimensionalTranscriptome sequencingInvasion ratioFibroblast-like synoviocytesCartilageGene overexpressionGenesDrug screeningInvasion of cartilageInvasive capacityEfficient in vitro modelA comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease
Yildirim M, Keskinocak P, Hinderstein S, Tran K, Dasthagirisaheb Y, Madoff L, Pelton S, Yildirim I. A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease. Vaccine 2025, 47: 126692. PMID: 39778476, DOI: 10.1016/j.vaccine.2024.126692.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccineClinical presentationInvasive diseasePneumococcal diseaseAnnual incidence of invasive pneumococcal diseaseIncidence of invasive pneumococcal diseaseInvasive capacityInvasive pneumococcal disease serotypesPost-PCV13 eraReduced invasive diseasePneumococcal nasopharyngeal colonizationYears of ageNP carriageSerotype 35BPost-PCV13Respiratory seasonsCarriage prevalenceNasopharyngeal colonizationStreptococcus pneumoniaeConjugate vaccineSerotype 18CAnnual incidenceVaccination strategiesNP isolates
2022
Intersections of endocrine pathways and the epithelial mesenchymal transition in endometrial cancer
Gelissen JH, Huang GS. Intersections of endocrine pathways and the epithelial mesenchymal transition in endometrial cancer. Frontiers In Oncology 2022, 12: 914405. PMID: 36052252, PMCID: PMC9424890, DOI: 10.3389/fonc.2022.914405.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEpithelial-mesenchymal transitionEndometrial cancerMesenchymal transitionRegulation of EMTTherapeutic interventionsInvasive capacityCancer metastasisEpithelial originEndocrine pathwaysMesenchymal phenotypeCancerCancer cellsEndocrine signalingMetastasisSignaling pathwaysCritical regulatorMortalityPathwayPotential avenues
2021
Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy
Terranova C, Tang M, Maitituoheti M, Raman A, Ghosh A, Schulz J, Amin S, Orouji E, Tomczak K, Sarkar S, Oba J, Creasy C, Wu C, Khan S, Lazcano R, Wani K, Singh A, Barrodia P, Zhao D, Chen K, Haydu L, Wang W, Lazar A, Woodman S, Bernatchez C, Rai K. Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. Cell Reports 2021, 36: 109410. PMID: 34289358, PMCID: PMC8369408, DOI: 10.1016/j.celrep.2021.109410.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell Line, TumorCell ProliferationChromatinEnhancer of Zeste Homolog 2 ProteinFemaleGTP PhosphohydrolasesHistonesHumansMelanocytesMelanomaMembrane ProteinsMesodermMice, NudeMitogen-Activated Protein Kinase KinasesMutationNeoplasm MetastasisPolycomb Repressive Complex 2Transcription, GeneticTumor BurdenConceptsHistone H3 lysine 27 trimethylationH3 lysine 27 trimethylationBivalent chromatin stateCell identity genesLysine 27 trimethylationKey epigenetic alterationsNRAS mutantsMaster transcription factorBivalent domainsChromatin statePRC2 inhibitionEpigenetic elementsTranscription factorsEpigenetic alterationsGenetic driversMesenchymal phenotypeNRAS-mutant melanomaState profilingTherapeutic vulnerabilitiesInvasive capacityPharmacological inhibitionMutantsTherapeutic strategiesMelanoma samplesMutant melanoma patients
2017
Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness
Yildirim I, Little BA, Finkelstein J, Lee G, Hanage WP, Shea K, Pelton SI, T, Health H. Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness. Vaccine 2017, 35: 4002-4009. PMID: 28645717, DOI: 10.1016/j.vaccine.2017.05.077.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccineInvasive disease potentialPneumococcal diseaseLow invasive capacityInvasive capacityPCV13 eraCommon serotypesIncidence of IPDNasopharyngeal colonization ratePost-vaccine eraDisease potentialCarriage serotypesPCV eraConjugate vaccineNasopharyngeal carriageCarriage prevalencePneumococcal colonizationEnhanced surveillanceDynamic epidemiologyAge groupsSerotype 3Serotype XOlder childrenLow invasiveness
2016
miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis
Xue J, Zhou A, Wu Y, Morris S, Lin K, Amin S, Verhaak R, Fuller G, Xie K, Heimberger A, Huang S. miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis. Cancer Research 2016, 76: 4293-4304. PMID: 27246830, PMCID: PMC5033679, DOI: 10.1158/0008-5472.can-15-3073.Peer-Reviewed Original ResearchConceptsProtocadherin-8Glioma tumorigenesisProtein-coding genesMiRNA gene transcriptionCandidate target genesExpression of STAT3Gene transcriptionBioinformatics analysisTarget genesSTAT3/miRSTAT3 knockdownPCDH8 expressionSTAT3 inhibitorAberrant activationGlioblastoma tissuesSTAT3Expression levelsInvasive capacityTranscriptionTumorigenesisGlioma progressionGenesCritical roleKnockdownP-STAT3
2010
Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease
Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, Huang SS, Lee GM, Kleinman K, Pelton SI. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 2010, 29: 283-288. PMID: 21029807, PMCID: PMC3139683, DOI: 10.1016/j.vaccine.2010.10.032.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseInvasive capacityPneumococcal diseaseIncidence of IPDNew pneumococcal conjugate vaccinesPneumococcal conjugate vaccineSterile body sitesStreptococcus pneumoniae serotypesCarriage serotypesNasopharyngeal acquisitionNP carriagePCV eraReplacement serotypesIPD incidenceRespiratory seasonsConjugate vaccineMassachusetts childrenCarriage prevalenceCommon serotypesPneumoniae serotypesOngoing surveillanceEnhanced surveillanceBody sitesPersistent reductionSerotype X
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply